Botanix Pharmaceuticals Ltd banner

Botanix Pharmaceuticals Ltd
ASX:BOT

Watchlist Manager
Botanix Pharmaceuticals Ltd Logo
Botanix Pharmaceuticals Ltd
ASX:BOT
Watchlist
Price: 0.045 AUD 7.14% Market Closed
Market Cap: AU$99.8m

Multiples-Based Value

The Multiples-Based Value for Botanix Pharmaceuticals Ltd (BOT) under the Base Case is 0.183 AUD. Compared with the current market price of 0.045 AUD, the stock appears Undervalued by 75%.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BOT Multiples-Based Value
Base Case
0.183 AUD
Undervaluation 75%
Multiples-Based Value
Price AU$0.045
Worst Case
Base Case
Best Case

Multiples Across Competitors

BOT Competitors Multiples
Botanix Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Botanix Pharmaceuticals Ltd
ASX:BOT
99.8m AUD 4.6 -1.1 -0.9 -0.9
US
Eli Lilly and Co
NYSE:LLY
901.8B USD 13.8 43.7 29.5 31.4
US
Johnson & Johnson
NYSE:JNJ
587.8B USD 6.2 21.9 15.2 18.7
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.1 19.7 11.6 13.1
UK
AstraZeneca PLC
LSE:AZN
233B GBP 5.3 30.7 16.9 23.9
US
Merck & Co Inc
NYSE:MRK
299B USD 4.6 16.4 10.1 12.3
CH
Novartis AG
SIX:NOVN
235.8B CHF 5.4 21.6 13.4 17.2
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.4 10.3 7.6 9
US
Pfizer Inc
NYSE:PFE
162.3B USD 2.6 20.9 7.9 10.6
US
Bristol-Myers Squibb Co
NYSE:BMY
124.3B USD 2.6 17.6 7.4 9.1
P/E Multiple
Earnings Growth PEG
AU
Botanix Pharmaceuticals Ltd
ASX:BOT
Average P/E: 22.5
Negative Multiple: -1.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
43.7
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
21.9
7%
3.1
CH
Roche Holding AG
SIX:ROG
19.7
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
30.7
26%
1.2
US
Merck & Co Inc
NYSE:MRK
16.4
14%
1.2
CH
Novartis AG
SIX:NOVN
21.6
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
1%
10.3
US
Pfizer Inc
NYSE:PFE
20.9
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17.6
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Botanix Pharmaceuticals Ltd
ASX:BOT
Average EV/EBITDA: 49.5
Negative Multiple: -0.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
29.5
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
15.2
2%
7.6
CH
Roche Holding AG
SIX:ROG
11.6
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
16.9
13%
1.3
US
Merck & Co Inc
NYSE:MRK
10.1
3%
3.4
CH
Novartis AG
SIX:NOVN
13.4
5%
2.7
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.6
1%
7.6
US
Pfizer Inc
NYSE:PFE
7.9
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.4
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Botanix Pharmaceuticals Ltd
ASX:BOT
Average EV/EBIT: 108.7
Negative Multiple: -0.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
31.4
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
18.7
6%
3.1
CH
Roche Holding AG
SIX:ROG
13.1
6%
2.2
UK
AstraZeneca PLC
LSE:AZN
23.9
21%
1.1
US
Merck & Co Inc
NYSE:MRK
12.3
6%
2.1
CH
Novartis AG
SIX:NOVN
17.2
9%
1.9
IE
E
Endo International PLC
LSE:0Y5F
941.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9
2%
4.5
US
Pfizer Inc
NYSE:PFE
10.6
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
9.1
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett